中药通淋逐瘀汤配合静滴阿奇霉素及克林霉素治疗慢性前列腺炎合并增生的临床研究

The Clinical Study of the Treatment of Chronic Prostatitis Hyperplasia by Combining Traditional Chinese Medicine Stasis Tonglin Soup with Intravenous Azithromycin and Clindamycin

摘要: 目的：观察通淋逐瘀汤(简称通淋汤)配合静滴阿奇霉素及克林霉素治疗慢性前列腺炎(CPS)合并增生(BPH) (简称前列腺炎合并增生)的临床疗效观察研究。方法：将CPS合并BPH125例患者随机分为通淋逐瘀汤配合静滴阿奇霉素及克林霉素中西医结合治疗组(以下简称治疗组) 50例，单用前列康胶囊(浙江康恩贝制药股份有限公司生产)对照治疗35例(对照1组)和单用三金片(桂林三金药业股份有限公司生产)对照治疗40例(对照2组)，比较3组的临床疗效。结果：治疗组对CPS合并BPH的总有效率为92%，明显高于对照1组(83%)和对照2组(78%)，治疗组疗效分别优于对照1组和对照2组，均为P < 0.05。结论：通淋逐瘀汤配合静点阿奇霉素及克林霉素中西医结合治疗CPS合并BPH，能迅速改善CPS合并BPH患者的症状，其临床疗效、症状好转率优于单用前列康胶囊或单用三金片治疗CPS合并BPH。

Abstract: The purpose of our research is to observe and study the clinical efficacy of chronic prostatitis (CPS) merger hyperplasia (BPH) (referred to as prostatitis hyperplasia) treated by Combining traditional Chinese medicine Tonglin Zhu Yu Tang with static drops of azithromycin and clindamycin. Methods: CPS merged BPH125 patients were randomized into stasis Tonglin soup with intravenous azithromycin and clindamycin combination therapy group (hereinafter referred to as the treatment group) 50 cases; alone forefront Capsule (Zhejiang Pharmaceutical CONBA Co., Ltd.) (control group 1) 35 cases; a single with three gold tablets (Guilin Sanjin Pharmaceutical Co., Ltd.) (control group 2) 40 cases, and compare the clinical efficacy of the three groups of treatment. Results: The effective rate of the treatment group for CPS BPH merger is 92%, significantly higher than the control group 1 (83%) and control group 2 (78%), indicating that treatment group is better than the control group 1 and control group 2, both P < 0.05. Conclusion: Stasis Tonglin soup with intravenous azithromycin and clindamycin combination therapy CPS merged BPH, can rapidly improve the CPS merger of BPH symptoms, its clinical efficacy, symptom improvement rate than single-use capsule or single Qianliekang Treatment with three gold pieces CPS merged BPH.